Ocular Allergy/Inflammation

FDA Approves Zerviate for Allergic Conjunctivitis

By June 01, 2017

Zerviate is the first topical ocular formulation of cetirizine.

Teprotumumab for Thyroid-Associated Ophthalmopathy

By May 04, 2017

Smith, TJ et al. "Teprotumumab for Thyroid-Associated Ophthalmopathy". DOI: 10.1056/NEJMoa1614949.

Tocilizumab Assessed for JIA-Associated Uveitis

March 17, 2017

Rapid and maintained improvement in all ocular parameters was seen with tocilizumab treatment.

Dextenza NDA Resubmission Accepted for Post-Surgical Ocular Pain

By February 23, 2017

The NDA for Dextenza was resubmitted in January 2017 following a Complete Response Letter that was issued in July 2016 due to concerns with deficiencies in manufacturing processes and controls.

Dextenza NDA Resubmitted for Post-Surgery Ocular Pain

By January 23, 2017

Ocular has announced that it has resubmitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Dextenza (dexamethasone insert) 0.4mg, to treat ocular pain after ophthalmic surgery.

Links Between Preeclampsia and Later Retinal Disease Examined

December 15, 2016

Preeclampsia is associated with increased risk of maternal retinal disease, especially traction detachments, retinal breaks, and diabetic retinopathy, according to a study published in the January issue of Obstetrics & Gynecology.

Results Released for Investigational Uveitis Therapy

By November 29, 2016

Santen has announced positive results from two Phase 3 trials of sirolimus intravitreal injection 440µg (Opsiria) for patients with non-infectious uveitis of the posterior segment.

Ocufen Eye Drops No Longer Available

By November 28, 2016

The Food and Drug Administration (FDA) has posted a discontinuation notice for Ocufen (flurbiprofen sodium ophthalmic solution; Allergan) 0.03% and its authorized generic.

Anti-VEGF Agents Efficacy Compared in Diabetic Macular Edema

By November 04, 2016

A post-hoc analysis of a randomized clinical trial comparing three anti-vascular endothelial growth factor (VEGF) agents, found that intravitreous aflibercept was associated with the greatest improvement in visual acuity (VA) over 2 years, for patients with diabetic macular edema (DME).